Reuters Health, Author at PharmaLive

About Reuters Health

This author has not written his bio yet.
But we are proud to say that Reuters Health contributed 4394 entries already.

Entries by Reuters Health

U.S. reports 60 new measles cases in worst outbreak since 1994

The most widespread U.S. measles outbreak in a quarter-century has infected 60 new patients in the last week, raising the total number of confirmed cases to 764, federal health officials said.

May 6, 2019/by Reuters Health

Analysts, Approvals, Breakthrough Therapy Designation, Clinical Data, Familial Amyloid Polyneuropathy (FAP), FDA, FDA/Regulatory, Heart Disease, Neurodegenerative Diseases, Potential Blockbusters, Transthyretin amyloid cardiomyopathy

Pfizer gets U.S. approval for $225,000 a year heart drug

The U.S. Food and Drug Administration approved Pfizer Inc.’s oral drug tafamidis to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy.

May 6, 2019/by Reuters Health

District Courts, Patent Infringement

UK’s Vectura wins patent infringement case against GlaxoSmithKline in U.S.

British drugmaker Vectura Group Plc won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and was awarded $89.7 million in damages for the period from August 2016 through December 2018.

May 4, 2019/by Reuters Health

Analyst Estimates, Blockbusters, Blood Sugar, Business, Glucagon-Like Peptide-1 (GLP-1) Analogs, Injections, Patent Protection, Shares, Type 2 Diabetes, Weight

Novo Nordisk Q1 2019 profit tops forecast

Danish drugmaker Novo Nordisk beat first-quarter 2019 operating profit forecasts, helped by higher sales of the company’s biggest new drug hope, a treatment for type 2 diabetes.

May 3, 2019/by Reuters Health

Acquisitions, Analysts, Business, CAR-T Therapy, Cell Therapy, Financials, Hepatitis C, HIV, Liver Damage, Lymphomas, Product Pipeline, Quarterly results, Shares, Wall Street

Gilead to separate Kite cell therapy unit

Gilead Sciences Inc. said Kite Pharma Inc., the cancer-focused cell therapy company acquired in 2017, will become a separate business unit.

May 2, 2019/by Reuters Health

Crisis, Doctors, Opioids, Painkillers

Founder, execs of drug company guilty in conspiracy that fed opioid crisis

The founder of Insys Therapeutics Inc. became the highest-ranking pharmaceutical executive to be convicted in a case tied to the U.S. opioid crisis, when he and four colleagues were found guilty of participating in a scheme to bribe doctors to prescribe an addictive painkiller.

May 2, 2019/by Reuters Health

"Closed Triple" Therapies, Analysts, Asthma, Clinical Trials, COPD, FDA, Generics, Inhalers, Lung Functions, R&D

GSK’s 3-in-1 inhalable drug shows promise in asthma study

GlaxoSmithKline Plc said the company’s three-in-one drug Trelegy Ellipta met the main goal of a late-stage asthma study, signaling a possible boost to the British drugmaker’s lung medicines division.

May 2, 2019/by Reuters Health

Autism, Bills, Business, California, Children, Department of Health and Human Services (HHS), House of Representatives, Immunizations, Iowa, Maine, Measles, Minnesota, New Jersey, New York, Oregon, Outbreaks, Scientific studies, State Legislation, Vaccines

As measles returns, U.S. states look to cut vaccine exemptions

Maine could soon prohibit parents from citing religious or personal beliefs to avoid vaccinating their children, making the U.S. state one of a half dozen cracking down during the nations’ largest measles outbreak in 25 years.

May 2, 2019/by Reuters Health

Attorneys General, Business, Drug Distributors, Epidemics, Lawsuits, McKesson, Opioids, Painkillers, Pharmacies, West Virginia

McKesson to pay $37 million to resolve West Virginia opioid lawsuit

Drug distributor McKesson Corp. agreed to pay $37 million to resolve a lawsuit by the state of West Virginia seeking to hold the company responsible for contributing to the opioid epidemic, the state’s attorney general said.

May 2, 2019/by Reuters Health

Analysts, Business, Financials, Forecasts, Generics, Health Insurance, Huntington’s Disease, Job Cuts, Migraine, Multiple Sclerosis, Pharmacy Benefit Managers, Prescriptions, Quarterly results, Shares

Teva migraine drug helps to contain profit fall

Teva Pharmaceutical Industries posted a slightly smaller than expected drop in first-quarter 2019 profit and forecast a sharp rise in 2020 revenue from the company’s new migraine drug Ajovy.

May 2, 2019/by Reuters Health